Form 4 for ROIV Roivant Sciences Ltd.
Accepted 2026-01-22 00:00:00 ET · period of report 2026-01-20 · accession 0001140361-26-002087 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-22 | 2026-01-20 | ROIV | MOMTAZEE JAMES C | Dir | F - Tax | $22.98 | -122 | 109.0K | -0.1% | -$2,804 | |
| 2026-01-22 | 2026-01-20 | ROIV | MOMTAZEE JAMES C | Dir | A - Grant | $0.00 | +609 | 109.2K | +0.6% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2026-01-20 | F | D | 122 | $22.98 | 109,030 | D | — | — | (F2) Represents the "net settlement" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares. |
| 2 | Common | Common Shares | 2026-01-20 | A | A | 609 | $0.00 | 109,152 | D | — | — | (F1) Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date. |